Clinical Trials Browser

Phase 1/2 × INDUSTRY × dostarlimab × Clear all

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06879717 2026-01-16

PULMO-01

Phase 1/2 Active not recruiting

45 enrolled

Thoracic

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1/2 Active not recruiting

83 enrolled

CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT06796907 2025-10-14

BEHOLD-2

Phase 1/2 Recruiting

392 enrolled

Tumor-Agnostic

Neoplasms

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT05060432 2024-06-21

TIG-006

Phase 1/2 Active not recruiting

153 enrolled

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma